PhotoPharmics is conducting a clinical trial to establish the safety and efficacy of a non-invasive device designed to restore health to Parkinson's patients.
Photopharmics provides specialized, non-invasive phototherapy device which allows dopamine to be assimilated by Parkinson's patients. A number of trials, including a 4-year, 130 patient study, demonstrate dramatic symptomatic improvement and continued improvement over the long term. This has never been seen in PD treatment. PPI is conducting a multi-national trial to establish the safety and efficacy of this novel therapy.